Adma Biologics, Inc. (ADMA) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
High 9.15 at 5:00 am ET, low 8.83 at 9:45 am ET.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
the bull case· 3
+25.32%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26322
managers reporting a position in thirteen F filings
13fJun 30 '264
funds on file reporting a position in ADMA
n-portas of Jun 30 '26the bear case· 4
36.50%
revenue from the largest disclosed customer BioCare Inc
10-Kfiled Feb 25 '269 of 23
largest reporting managers cutting their stake in the latest quarter
13fJun 30 '267 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized32
managers whose positions together make up four fifths of reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 11 '26 report. Not a forecast, not advice.
Of the 6 companies Adma Biologics, Inc. moves with most closely, none share its SEC classification.
Measured against 193 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
Adma Biologics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
tall tick = annual report · 2 on record
321 managers report a position worth $1.7B between them, and 32 of them hold 80% of it.
ADMA (Adma Biologics, Inc.) has 4 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.